- Company utilizing novel Caribbean blue scorpion venom therapy for immune system boost
- PreveCeutical seeks new ways to treat cancers, metabolic disorders, pain, infectious diseases and cardiovascular disease
- Partnership with University of Queensland researchers advances scientific scope of projects
In the modern health care industry, disease prevention has taken a commanding role as screenings and regularly scheduled physician visits aim to minimize costs that could otherwise spiral out of control once a chronic condition is established. However, the Centers for Disease Control and Prevention report an ongoing concern that Americans are using preventive services at about half the recommended rate (http://cnw.fm/OIa4V). British Columbia-based PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was founded on the principle that prevention is the best policy in health care and that nature and science may combine to provide an array of innovative, untapped solutions to otherwise unmet clinical needs.
PreveCeutical is taking a new look at ways to combat chronic health concerns such as diabetes and obesity, pain management, neurological disorders and cancer. PreveCeutical developed its CELLB9® oral dilute solution utilizing select peptides from the blue scorpion, which is found only in the Caribbean region. PreveCeutical’s “Nature Identical” research team is building on proprietary chemistry to produce controlled venom peptides that it hopes will be able to halt…
More from CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com